Oropharyngeal Dysphagia in Infants and Children with Infantile Pompe Disease
- 10 September 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Dysphagia
- Vol. 25 (4), 277-283
- https://doi.org/10.1007/s00455-009-9252-x
Abstract
Pompe disease is a rare genetic progressive neuromuscular disorder. The most severe form, infantile Pompe disease, has historically resulted in early mortality, most commonly due to cardiorespiratory failure. Treatment with enzyme replacement therapy (ERT) using alglucosidase alfa (Myozyme®) has extended the lifespan of individuals with this disease. With the introduction of ERT and the resultant improved survival, dysphagia is being encountered clinically with increasing regularity though systematic data remain unavailable. We retrospectively studied the oropharyngeal swallowing of 13 infants and children with Pompe disease using videofluoroscopy before initiation of ERT, allowing for baseline swallow function to be established in an untreated cohort. Dysphagia was present in all 13 subjects, even in a participant only 15 days old. Oral stage signs were present in 77%, most frequently a weak suck in 69%. Pharyngeal stage signs were present in 100%, including a pharyngeal swallow delay in 92% and pharyngeal residue in 77%. Airway invasion was present in 76.9% of subjects, including penetration in five (38.46%) and silent aspiration in an additional five (38.46%). No relationship in the relative involvement of swallowing, gross motor function, and cardiac disease appeared to be present.Keywords
This publication has 23 references indexed in Scilit:
- A Novel Method of Expressing Left Ventricular Mass Relative to Body Size in ChildrenCirculation, 2008
- Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case seriesPediatric Anesthesia, 2007
- Glycogen storage disease types I and II: Treatment updatesJournal of Inherited Metabolic Disease, 2007
- Pediatric Feeding and Swallowing Problems: An Interdisciplinary Team ApproachCanadian Journal of Dietetic Practice and Research, 2006
- Chinese hamster ovary cell-derived recombinant human acid α-glucosidase in infantile-onset Pompe diseaseThe Journal of Pediatrics, 2006
- Pompe disease diagnosis and management guidelineGenetics in Medicine, 2006
- Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of CardiologyJournal of the American Society of Echocardiography, 2005
- Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trialNeuromuscular Disorders, 2005
- Pompe disease in infants and childrenThe Journal of Pediatrics, 2004
- The Natural Course of Infantile Pompe’s Disease: 20 Original Cases Compared With 133 Cases From the LiteraturePediatrics, 2003